Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species | Zendy

Maiken Cavling Arendrup | Zendy; Gunnar Kahlmeter | Zendy; Juan L. Rodrı́guez-Tudela | Zendy; J. Peter Donnelly | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species

Author(s) -

Maiken Cavling Arendrup,

Gunnar Kahlmeter,

Juan L. Rodrı́guez-Tudela,

J. Peter Donnelly

Publication year - 2009

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01624-08

Subject(s) - fluconazole , biology , candida glabrata , breakpoint , variation (astronomy) , antifungal , microbiology and biotechnology , genetics , gene , physics , astrophysics , chromosomal translocation

The fluconazole MIC distributions for Candida glabrata from testing 34 different clinical isolates and performing 51 tests on a single isolate mirrored each other. Since what is perceived as biological variation in isolates without resistance mechanisms is mainly methodological variation, breakpoints which divide this distribution not only lack a sound biological basis but also result in poor reproducibility of susceptibility characterization. This makes 2, 4, 8, and possibly 16 microg/ml unsuitable breakpoints for C. glabrata and fluconazole.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research